Brief: Newron Completes Enrollment Of Schizophrenia Patients In Potentially Pivotal Study 008A With Evenamide
29/12/2023 12:14
Dec 29 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* NEWRON COMPLETES ENROLLMENT OF SCHIZOPHRENIA PATIENTS IN
POTENTIALLY PIVOTAL STUDY 008A WITH EVENAMIDE
* RESULTS FROM STUDY ARE EXPECTED IN MARCH 2024
Source text for Eikon: ID:nBwYpwhma
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study